Healthcare Industry News: Riverain Medical
News Release - February 16, 2011
Study Shows Improved Detection of Lung Cancer Nodules with Riverain Medical’s CAD Chest X-ray TechnologyDAYTON, Ohio--(Healthcare Sales & Marketing Network)-- Riverain Medical, an industry leader and innovator in computer-aided detection (CAD) and advanced visualization technologies, today announced a poster presentation, “A Superior Chest X-Ray Computer-Aided Detection (CXR CADe) Application: A Reader Study,” has been published on the European Society of Radiology’s website. Investigators compared two versions of Riverain Medical’s computer-aided detection (CAD) technology, OnGuard™ 5.1 and OnGuard 1.0. The study found radiologists using OnGuard 5.1 were able to detect smaller lung nodules, including those that were primary lung cancer.
“By using OnGuard 5.1 in tandem with a standard chest X-ray, our radiologists are now able to detect smaller lung nodules that would have previously gone unnoticed,” said Dr. Matthew Freedman, principal investigator of the study and Associate Professor of oncology at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C. “It’s clear from our research that OnGuard CAD technology has improved significantly over the past 10 years. Improved sensitivity and a lower false positive rate allow radiologists to detect early-stage lung cancer sooner, giving them more confidence in diagnosing the patient.”
Fifteen radiologists participated in the reader study, which analyzed more than 250 chest X-rays (approximately a 2:1 cancer negative to positive ratio). Compared to its previous version, investigators found OnGuard 5.1 provided nearly 50 percent higher machine sensitivity for cancer detection, while significantly reducing the number of false positives per image.
“Initial results of the National Lung Screening Trial demonstrate for the first time that the early detection of lung cancer can save lives,” said Steve Worrell, chief technology officer of Riverain Medical. “We’re excited to play a key role in the early detection of lung cancer. OnGuard’s CAD markings give radiologists a second set of eyes, allowing radiologists to find cancerous nodules at their earliest and most treatable stage.”
For more information on OnGuard, please visit http://www.riverainmedical.com or visit Riverain Medical at booth #552 Expo E at the European Society of Radiology’s annual meeting ECR 2011, which will take in Vienna, Austria from March 3–7, 2011.
About Riverain Medical
Riverain Medical is a medical device company developing enhanced chest imaging technologies that aid in the detection of lung disease, including lung cancer. Riverain Medical’s software solutions make traditional digital chest X-rays even better. Our FDA approved OnGuard is an advanced computer-aided detection (CAD) technology that identifies areas on a chest X-ray that may be early-stage lung cancer. FDA cleared SoftView technology uses advanced algorithms to suppress bone on X-rays, providing 40 percent greater visibility of the chest area, to improve the clarity of soft tissue. For more information please visit: http://www.riverainmedical.com.
Source: Riverain Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.